Prostate Cancer

[unable to retrieve full-text content] Best Prostate Supplements: Top 11 Prostate Health Support Products Ranked    The Tribune India

January was a busy month for the FDA and the field of oncology as the agency approved 5 therapies, including tucatinib (Tukysa), zanubrutinib (Brukinsa), pembrolizumab (Keytruda) in the later stages of non–small cell lung cancer (NSCLC), pirtobrutinib (Jaypirca), and elacestrant (Orserdu). The agency also granted 3 orphan drug designations for novel therapies impacting patients with melanoma, skin cancer, and glioblastoma (GBM). Moreover, the FDA is continuing its review of new ways to treat patients with cancer with multiple priority reviews granted after the submission HBM1020 of biologics license applications (BLAs) for cosibelimab (formerly CK-301) and glofitamab OverC™ Multi-Cancer Detection Blood Test (RG6026). Additionally, the FDA granted 3 fast track designations and 2 breakthrough designations to therapies in ongoing studies. The FDA also continued to approve companion diagnostics that are a part of identifying patients to their respective treatments with a breakthrough desig

Y&T frontman Dave Meniketti , who went public with his prostate cancer battle in February 2022, says that he is in complete remission after receiving radiation. Earlier today, the 69-year-old guitarist/vocalist took to his Twitter to share a new selfie, and he included the following message: "Just thought I'd update those of you who have been curious about my prostate cancer diagnosis last year, of which I finished treatments for back in July. This morning, I just had a follow up with my oncologist. From his mouth – I am in total remission!" According to the National Cancer Institute , remission means that the signs and symptoms of the cancer are reduced. Remission can be partial or complete. In a complete remission, all signs and symptoms of cancer have disappeared. If the patient remains in complete remission for five years or more, some doctors may say that the patient is cured. Y&T frontman Dave Meniketti , who went public with his prostate cancer b

[unable to retrieve full-text content] Photoactivatable nanoagonists chemically programmed for ...    pnas.org

NEW YORK — Researchers from McGill University and elsewhere have developed an approach to predict from just a small tumor tissue sample which lung cancer patients will progress following surgery. Specifically, they combined imaging mass cytometry with deep learning to analyze the tumor microenvironment of lung cancer samples from more than 400 lung adenocarcinoma patients. That environment, they noted, has been identified as a source of heterogeneity that affects treatment response and disease progression. By characterizing the tumor microenvironment spatially and at the single-cell level, the researchers were able to uncover different cellular states and features associated with clinical characteristics such as survival. As they reported in Nature on Wednesday, they then used artificial intelligence to identify which of these features of the tumor microenvironment could predict disease progression with high accuracy. "Overall, these data suggest that spatially resolved s

Pityriasis rosea is a rash that typically appears on the upper arms and legs, trunk, or neck. It is sometimes confused with a type of psoriasis called guttate psoriasis because skin symptoms of each might appear similar.  Guttate psoriasis appears as red, scaly, small, teardrop-like spots on the skin. It primarily affects children and young adults. It sometimes means that you might develop plaque psoriasis later on. Psoriasis is considered an autoimmune skin disease that occurs when the immune system malfunctions and starts to attack healthy tissues, mainly the skin, which leads to accelerated skin cell growth. This article covers the similarities and differences between pityriasis rosea and guttate psoriasis, including symptoms, diagnosis, treatment, and more. Pityriasis Rosea and Psoriasis Aren't the Same Pityriasis rosea and psoriasis have some things in common. They also differ in many ways. Similarities  Pityria

Francis P. Worden, MD (Comoderator) Clinical Professor University of Michigan Health Ann Arbor, MI Ian Maher, MD (Comoderator) Professor Director of Dermatology Mohs Fellowship Director University of Minnesota Medical School Minneapolis, MN CASE SUMMARY A man aged 88 years presented with a nonhealing ulcer on the lateral aspect of his nose. Ten years prior, he had surgical excisions of 2 nodular basal cell carcinomas (BCCs) of the trunk (0.4 × 0.4 cm and 0.5 × 0.8 cm, both with no perivascular or perineural invasion). Biopsy demonstrated infiltrative BCC. The multidisciplinary team is not in favor of surgery or radiotherapy for this lesion based on its size and location. After treatment options were discussed with the patient, the patient declined radiotherapy or surgery. DISCUSSION QUESTIONS What do you view as the pros and cons of each treatment option for locally advanced/metastatic BCC? Have you used a Hedgehog pathway inhibitor (HHI) in your practice? If yes, please discuss your e

Specialty

[unable to retrieve full-text content] These 3 diseases may lead to breast cancer. What are they?    KBR

Two antibody drug conjugates (ADCs), ARX788 and ARX517, are being further investigated to address unmet medical needs for patients with breast cancer and prostate cancer. 1 During the virtual analyst and investor day on February 24, 2023, experts, including Hope S. Rugo, MD, FASCO, and Paula R. Pohlmann, MD, MS, PhD, discussed what has already been seen with ARX788 for patients with HER2-positive metastatic breast cancer, and what their expectations are for the agent moving forward. Then, the first-in-human APEX-01 trial (NCT04662580) was highlighted, and the role of ARX517 for patients with prostate cancer, a proprietary anti-PSMA ADC, was discussed. While trastuzumab deruxtecan (Enheurtu; T-DXd) has shown benefits in patients with breast cancer, data has shown that 24.2% of patients progress while on the agent within 12 months. At 12 months, the progression-free survival (PFS) was 75.8 months (95% CI, 69.8-80.7) with T-DXd and 34.1 months (95% CI, 27.7-40.5) with trastuzumab emtansin

Matthew Galsky, MD At extended follow-up, nivolumab monotherapy showed improved disease-free survival (DFS), non-urothelial tract recurrence-free survival (NUTRFS), and disease-specific survival (DSS) vs placebo in patients with resected, high-risk muscle-invasive urothelial carcinoma, according to results from the phase 3 CheckMate 274 study (NCT02632409) presented at the 2023 Genitourinary Cancers Symposium. In the intent to treat (ITT) population at a median follow-up of 36.1 months vs 33.9 months, respectively, nivolumab continued to yield DFS improvements vs placebo, including in patients with a PD-L1 expression of 1% or more. The median DFS in the nivolumab arm was 22.0 months (95% CI, 18.8-36.9) vs 10.9 months (95% CI, 8.3-15.2) in the placebo arm (Hazard ratio [HR], 0.71; 95% CI, 0.58-0.86). In the population with a PD-L1 expression of 1% or more, the median DFS was 52.6 months (95% CI, 25.8-not estimable [NE]) and 8.4 months (95% CI, 5.6-17.9), respectively (HR, 0.52; 95% CI,

Specialty

Lung adenocarcinoma is a type of non-small cell lung cancer (NSCLC). This cancer is the most common form of NSCLC, and it can occur in people who smoke and those who do not. Adenocarcinoma is a subtype of NSCLC that begins in mucus-producing cells. This form of NSCLC typically occurs in the outer areas of the lung. Lung adenocarcinoma can respond well to treatment when caught before it has spread to other body parts. There are two main categories of lung cancer: small cell lung cancer and NSCLC. Roughly 80–85% of lung cancer cases are NSCLC. This article will examine lung adenocarcinoma, the symptoms, causes, who is most at risk, diagnosis, stages, treatment options, outlook, and frequently asked questions. Lung adenocarcinoma begins in glandular cells found in the outer regions of the lungs. These cells are responsible for producing substances such as digestive fluids and mucus. The severity of lung adenocarcinoma depends on the cancer stage. In the early stages, cancer occurs in a l